3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Dermatologic
3
Gastrointestinal
2
Head & Neck
1
Gynecologic
1
Conditions
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
84
Cisplatin
73
Cetuximab
54
Radiotherapy
41
Nivolumab
31
Radiotherapy, Intensity-Modulated
26
Docetaxel
26
Fluorouracil
23
Cyclophosphamide
23
Paclitaxel
22
fludarabine
19
Radiation
18
Gemcitabine
18
Carboplatin
18
Magnetic Resonance Spectroscopy
16
Erlotinib Hydrochloride
16
durvalumab
15
atezolizumab
13
fludarabine phosphate
10
Radiosurgery
10
Specimen Handling
9
Interleukin-2
9
Drug Therapy
9
Biopsy
9
130-nm albumin-bound paclitaxel
9
budigalimab
8
Ipilimumab
8
Bortezomib
8
tremelimumab
7
toripalimab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
naporafenib
×
Head & Neck
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled